| Name | Title | Contact Details |
|---|---|---|
Claudia Kuri |
Chief Operating Officer | Profile |
Glenn Galloway |
Executive VP Technology & Integrations | Profile |
Palo Pinto General Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Palo Pinto General Hospital is based in Mineral Wells, TX. You can find more information on Palo Pinto General Hospital at www.ppgh.com
Devoted Health is a new healthcare company serving seniors. Our mission is to build a health care plan that treats every member like they were one of our own family. We are devoted to the health and wellness of our members by helping them navigate the healthcare system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.
We are dedicated to delivering high-quality, affordable health care services in a compassionate environment that meets each patient`s physical, mental and spiritual needs. Upholding the core values of dignity, justice, stewardship, collaboration, and excellence, our healing philosophy serves not just our patients, but our staff, our communities, and our planet. At Dignity Health a family of more than 60,000 caregivers and staff are delivering excellent care to diverse communities across 17 states. Founded in 1986 and headquartered in San Francisco Dignity Health is the fifth largest hospital provider in the nation and the largest hospital system in California. Through teamwork and innovation, faith and compassion, advocacy and action, we endeavor every day to keep you happy, healthy, and whole.
Danaher is a diversified technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.